• Read more about Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal Pneumonia and the Importance of Vaccination

NEW YORK, NY, September 17, 2019 - Football legend Terry Bradshaw and Pfizer are partnering for a second year on the All About Your Boom™ campaign with the goal of educating Baby Boomers about the risk for pneumococcal pneumonia. The campaign encourages adults aged 65 or older to speak with their healthcare provider about whether vaccination to help prevent pneumococcal pneumonia is right for them.

• Read more about TrialSpark and Pfizer collaborating to improve speed and access to clinical trials

New York, NY, Tuesday, September 17, 2019 – 08:03 am EDT

• Read more about Pfizer Statement on Results of Pay Equity Study and Opportunity Parity Among Colleagues Worldwide

NEW YORK, N.Y., October 17, 2019 – Pfizer Inc. (NYSE:PFE) stated today that a recognized compensation expert confirmed equitable pay practices at Pfizer, after accounting for employee role, education, experience, performance, and location and without regard to gender or race.

• Read more about Pfizer Announces CHMP Opinion for XELJANZ® (tofacitinib) in the European Union Related to Ongoing Review of the Product

NEW YORK, N.Y., November 15, 2019 – Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a final opinion following the re-evaluation of the benefit/risk of the three approved indications of XELJANZ in the European Union (Article 20 procedure).

• Read more about Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts

Pfizer will become the first company to bring three oncology monoclonal antibody (mAb) biosimilar treatments to the U.S. market

• Read more about Pfizer Provides Comment on COVID-19 White House Meeting

NEW YORK, March 2, 2020—Pfizer Inc. (NYSE: PFE) announced that today Pfizer’s Chief Scientific Officer Mikael Dolsten participated in a meeting with other pharmaceutical companies about various ways to develop vaccines and therapeutics for COVID-19 held at the White House.

Pfizer was pleased to have been part of the important meeting convened by the President, given the company’s leading research expertise, manufacturing capability and capacity, and regulatory experience, to help combat the virus.

• Read more about Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

NEW YORK, N.Y., May 1 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for DAURISMOTM(glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.

• Read more about Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Results Presented at the American Diabetes Association’s Virtual 80th Scientific  Sessions 

• Read more about NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY

Pfizer-funded research finds that 20 S. pneumoniae serotypes are associated with a substantial burden of pneumococcal disease globally^1,2,3

NEW YORK, June 23 - Pfizer Inc. (NYSE:PFE) today announced that new data on the evolving burden of S. pneumoniae serotypes will be included as part of an online digital library created by the International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) in place of its 2020 Scientific Program, which was postponed until 2021 due to the COVID-19 pandemic.

• Read more about Pfizer Statement on Facebook Advertising Boycott

NEW YORK, June 29, 2020 -- Pfizer issued a statement today in response to the proposed #StopHateForProfit boycott of Facebook advertising properties:

Today, we announced that we will be removing all of our advertising from Facebook and Instagram for the month of July. For us, it’s clear that to live our value of Equity, demonstrating respect for all people and making it clear that any hate speech is unacceptable, we must speak up and take action.